Allison Aubrey
Allison Aubrey is a correspondent for NPR News, where her stories can be heard on Morning Edition and All Things Considered. She's also a contributor to the PBS NewsHour and is one of the hosts of NPR's Life Kit.
Along with her NPR science desk colleagues, Aubrey is the winner of a 2019 Gracie Award. She is the recipient of a 2018 James Beard broadcast award for her coverage of 'Food As Medicine.' Aubrey is also a 2016 winner of a James Beard Award in the category of "Best TV Segment" for a PBS/NPR collaboration. The series of stories included an investigation of the link between pesticides and the decline of bees and other pollinators, and a two-part series on food waste. In 2013, Aubrey won a Gracie Award with her colleagues on The Salt, NPR's food vertical. They also won a 2012 James Beard Award for best food blog. In 2009, Aubrey was awarded the American Society for Nutrition's Media Award for her reporting on food and nutrition. She was honored with the 2006 National Press Club Award for Consumer Journalism in radio and earned a 2005 Medical Evidence Fellowship by the Massachusetts Institute of Technology and the Knight Foundation. In 2009-2010, she was a Kaiser Media Fellow.
Joining NPR in 2003 as a general assignment reporter, Aubrey spent five years covering environmental policy, as well as contributing to coverage of Washington, D.C., for NPR's National Desk. She also hosted NPR's Tiny Desk Kitchen video series.
Before coming to NPR, Aubrey was a reporter for the PBS NewsHour and a producer for C-SPAN's Presidential election coverage.
Aubrey received her Bachelor of Arts degree from Denison University in Granville, Ohio, and a Master of Arts degree from Georgetown University in Washington, D.C.
-
An independent advisory committee of the CDC is evaluating the need for a Pfizer booster dose — meeting one day after the FDA granted emergency use authorization for a booster dose in certain adults.
-
The Food and Drug Administration gave the OK for a Pfizer COVID-19 vaccine booster for anyone 65 or older or at high risk for severe disease. People whose work puts them at risk will also be eligible.
-
A smaller dose of Pfizer's COVID-19 vaccine is safe and effective for children ages 5 to 11, according to data the company released Monday. The data will now go before the FDA and CDC for review.
-
The U.S. is averaging about 140,000 new cases of coronavirus per day and about 1,500 people are dying each day from the virus. Amid this surge, the Biden administration's booster strategy is in flux.
-
The FDA has ruled on which e-cigarette products can remain on the market and which must be taken off, but deferred action on products made by Juul, which accounts for 40% of the e-cigarette market.
-
The FDA will rule on applications from e-cigarette makers who want to stay on the market. Advocates who sued the agency say products that contain flavors and high levels of nicotine should be banned.
-
The cancer risk is linked to exposure to toxins at ground zero. But the group is also more likely than the general public to survive, perhaps because of the comprehensive care they receive.
-
The Biden administration's COVID booster plan for the general population is supposed to start soon, but the FDA still wants to review its safety — and whether kids under 12 should be vaccinated.
-
Due to more mandates around the U.S., White House COVID advisors say first-time vaccination rates are now on the rise after a slowdown this summer. Millions of unvaccinated children are now in school.
-
Vaccines remain the best way to protect against serious illness. A week after the FDA gave full approval to Pfizer's COVID-19 vaccine, it's not known if that's nudging more people to get the shot.
-
The current COVID-19 surge shows few signs of abating. New coronavirus cases keep rising as hospitals remain crowded and even overrun.
-
A third shot will be offered to all adults vaccinated with Pfizer and Moderna vaccines, even though those vaccines still offer high protection against the delta variant.